COVID supplement: Tetramer Research & Development

新冠肺炎补充剂：四聚体研究

• 批准号: 10678174
• 负责人: JOHN ALTMAN
• 金额: $ 20万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-21 至 2027-03-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678174
• 关键词: 2019-nCoV; Antigen Presentation Pathway; Area; Bar Codes; Binding Sites; Biotin; Communicable Diseases; Communities; Contracts; Core Facility; DNA; Disease; Immune; Immunology; MHC Class II Genes; Mediating; Mesocricetus auratus; Oligonucleotides; Performance; Production; Reagent; Research; Resources; Stains; Streptavidin; T cell response; T-Cell Activation; T-Lymphocyte; Technology; Time; United States National Institutes of Health; Variant; coronavirus disease; cost; fluorophore; neoplastic cell; novel; pathogenic microbe; research and development

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology (such as SARS-CoV-2) and a wide variety of infectious disease areas via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.

NIH Tetramer Core Facility为研究界提供了宝贵的资源，通过生产和分销I类，II类和CD 1试剂，使基础免疫学（如SARS-CoV-2）和各种传染病领域的前沿研究成为可能。这些试剂正被应用于抗原加工和呈递、T细胞活化、T细胞对微生物病原体或肿瘤的应答以及T细胞介导的免疫介导疾病的恶化或改善的研究。该合同进行研究和开发，以提高质量，功能（例如，灵敏度）和可用四聚体试剂的宽度，并减少生产时间。